This review systematically summarizes antibody-based therapeutic strategies and tumor microenvironment characteristics in gallbladder cancer, providing key theoretical foundations for constructing preclinical models and validating biomarkers in future precision immunotherapy for gallbladder cancer.
Literature Overview
The article “Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review,” published in the journal *Antibodies*, systematically explores advances in antibody-targeted therapies and tumor microenvironment (TME) characteristics in gallbladder cancer (GBC). The review summarizes clinical evidence for monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates (ADCs) in GBC, while deeply analyzing TME heterogeneity, discrepancies in PD-L1 expression detection, and potential immune evasion mechanisms. It further examines the variable efficacy of HER2-targeted therapies in GBC and emphasizes the importance of population genetic backgrounds in epidemiological studies, such as the EULAT Eradicate GBC initiative's precision prevention strategies for high-risk populations. The article also discusses progress in identifying early diagnostic biomarkers, including autoantibodies and multiprotein signatures, offering direction for future translational research.Background Knowledge
Gallbladder cancer is a highly aggressive malignancy of the biliary system, often diagnosed at advanced stages due to nonspecific symptoms, resulting in low resectability rates and poor overall survival. Current first-line treatment relies primarily on cisplatin–gemcitabine (Cis-Gem) chemotherapy, which offers limited efficacy, with a median overall survival of approximately one year. Recently, immune checkpoint inhibitors combined with chemotherapy (e.g., durvalumab and pembrolizumab) have shown some survival benefit, but effective predictive biomarkers remain lacking. In targeted therapy, HER2 amplification is one of the most common targetable genomic alterations in GBC; however, heterogeneity in detection methods and positivity criteria across studies limits its clinical application. Additionally, the “stroma-enriched” phenotype of the TME may hinder T-cell infiltration and drug delivery, creating an immunosuppressive microenvironment. Therefore, precisely identifying patient populations who may benefit from ADCs or bispecific antibodies and overcoming TME-mediated resistance remain core challenges. This article integrates existing clinical data and molecular mechanisms to systematically evaluate the current status and challenges of antibody therapies in GBC, advocating for standardized biomarker detection and promoting precision prevention and treatment strategies based on population genetics.
Research Methods and Experiments
The authors employed a systematic literature review approach, integrating data from several pivotal clinical trials, including ABC-02, TOPAZ-1, KEYNOTE-966, HERIZON-BTC-01, and DESTINY-PanTumor02, to analyze the efficacy of different treatment regimens in biliary tract cancer (BTC) and GBC subgroups. The study focused on HER2-targeted therapies, comparing the impact of different detection methods (e.g., IHC vs. NGS) and expression levels (IHC 3+ vs. 2+) on treatment response, revealing a strong correlation between efficacy and protein expression levels. The authors also reviewed transcriptomic classifications of the TME and, using immunohistochemical data (e.g., PD-L1, PD-1 expression), analyzed the distribution of “cold” and “hot” immune phenotypes and their potential impact on immunotherapy response. Additionally, the study evaluated the potential of plasma proteomics-based multiprotein biomarker models combined with machine learning for early diagnosis, although these remain in the exploratory phase.Key Conclusions and Perspectives
Research Significance and Prospects
This study emphasizes the importance of consistent target expression levels and detection methods in drug development, particularly for HER2-targeted therapies, advocating for standardized IHC/NGS interpretation via central laboratories. For clinical monitoring, routine HER2 and PD-L1 testing in GBC patients is recommended, along with exploration of TMB and MSI status to guide personalized therapy. Furthermore, the genetic risk model proposed by the EULAT initiative offers a new paradigm for disease modeling. In the future, gene-edited animal models simulating Caucasian or Latin American genetic backgrounds could be developed to create more clinically relevant GBC models for evaluating intervention thresholds for prophylactic cholecystectomy.
Conclusion
This review comprehensively summarizes recent advances in antibody therapies and immunological profiling in gallbladder cancer, highlighting the clinical value of HER2 as a core therapeutic target while revealing challenges posed by detection heterogeneity and TME complexity. From bench to bedside, the study outlines a critical path toward precision medicine in GBC: first, advancing standardized biomarker testing protocols to ensure accurate patient stratification; second, developing early diagnostic models based on multi-omics integration to enhance screening sensitivity; and third, utilizing genetically engineered animal models to simulate diverse population genetic backgrounds, enabling validation of precision prevention strategies. These advances collectively form the cornerstone for improving outcomes in gallbladder cancer patients, particularly in high-incidence regions such as Chile and Bolivia, where integrating genetic risk assessment with targeted interventions could significantly reduce disease burden. This work not only guides the design of current clinical trials but also lays the theoretical foundation for next-generation antibody therapies and personalized vaccine development.
